Management of Telogen Effluvium in Young Women

First‑Line Topical Therapy

Initiate topical minoxidil 5 % (foam once daily or solution twice daily) at the initial visit for every patient with telogen effluvium, irrespective of the identified trigger. This regimen is the only hair‑loss treatment supported by high‑level evidence (Level B) and acts by prolonging the anagen phase, accelerating the telogen‑to‑anagen transition, and converting miniaturized hairs to terminal hairs. American Academy of Dermatology recommendation. 1

Inform patients that a transient increase in shedding typically occurs during weeks 2–8; this paradoxical shedding signals pharmacologic activity and should not lead to discontinuation of therapy. American Academy of Dermatology guidance. 2
Advise that efficacy should not be judged before 12 months of continuous daily use; many individuals require at least 6 months to notice clinical improvement. American Academy of Dermatology guidance. 2
Common adverse effects of topical minoxidil include scalp pruritus and flaking (more frequent with propylene‑glycol‑containing solutions) and facial hypertrichosis (more common with the 5 % formulation than with 2 %). American Academy of Dermatology guidance. 2

Order a comprehensive laboratory panel that includes serum ferritin, complete blood count, serum iron, vitamin B12, thyroid function tests, and total/free testosterone (measured by LC/MS and calculated via SHBG) to identify reversible contributors and to exclude underlying androgenetic alopecia. American Academy of Dermatology recommendation. 2

Consider oral minoxidil 0.625–1.25 mg daily when patients experience scalp irritation from topical formulations, have difficulty with daily application, or prefer systemic therapy. American Academy of Dermatology recommendation. [3][1]
The typical starting dose for adult women is 1.25 mg per day. American Academy of Dermatology guidance. 2
Advantages of oral minoxidil include ease of use, improved adherence, no impact on hairstyle, and avoidance of cutaneous absorption limitations. American Academy of Dermatology evidence. 1
Absolute contraindications: pheochromocytoma and acute myocardial infarction. American Academy of Dermatology safety list. 4
Hypersensitivity to minoxidil is also a contraindication. American Academy of Dermatology safety list. [3][2]
Precautions requiring cardiology or internal‑medicine consultation: history of arrhythmia and renal impairment or dialysis. American Academy of Dermatology safety list. [4][3]2
Reported oral‑minoxidil adverse effects: facial hypertrichosis (≈24 % incidence, dose‑dependent), transient shedding (≈16–22 %), mild peripheral edema (≈2 %), and acute vasodilation symptoms (dizziness, tachycardia, palpitations) that peak between days 3–7. American Academy of Dermatology safety data. 2

Platelet‑rich plasma may be offered as an adjunctive therapy; current evidence is limited and graded Level C. American Academy of Dermatology recommendation. 2
PRP requires multiple monthly sessions and is more invasive than oral minoxidil, positioning it as a second‑tier option. American Academy of Dermatology guidance. 4

Time Point	Recommended Actions	Evidence
Month 0 (Initial visit)	Start topical minoxidil 5 %; order comprehensive labs; counsel about expected shedding weeks 2–8; inquire about recent weight loss, medications, and stressors.	[2]
Month 3	Review laboratory results, begin targeted supplementation if deficiencies identified; assess early response and adherence; manage any adverse effects.	[2]
Month 6	Perform formal clinical assessment with standardized photographs; consider adding oral minoxidil if response is inadequate or topical therapy is poorly tolerated.	[4] & [2]
Month 12	Conduct final efficacy evaluation; if response remains insufficient despite trigger elimination and minoxidil therapy, investigate alternative diagnoses (early androgenetic alopecia, chronic telogen effluvium).	[4]

Discontinuation during early shedding (weeks 2–8). Emphasize that shedding is expected and indicates drug activity; continuation is essential. American Academy of Dermatology recommendation. 2
Premature efficacy assessment (<12 months). Set realistic expectations that stabilization may require ≥12 months; early assessment can lead to unnecessary treatment changes. American Academy of Dermatology recommendation. 2
Initiating oral minoxidil without cardiovascular screening. Always evaluate for pheochromocytoma, recent myocardial infarction, arrhythmia, and renal impairment before prescribing. American Academy of Dermatology safety protocol. [3][2]

If hair loss persists beyond 12 months despite trigger elimination and minoxidil therapy, reassess for underlying androgenetic alopecia by measuring androgen levels and performing a scalp biopsy to detect follicular miniaturization. American Academy of Dermatology guideline. 2